ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Molecular characterization based on tumor microenvironment-related signatures for guiding immunotherapy and therapeutic resistance in lung adenocarcinoma

Jie, Yamin; Wu, Jianing; An, Dongxue; Li, Man; He, Hongjiang; Wang, Duo; Gu, Anxin*; Mingyan, E.*哈尔滨医科大学
Frontiers in Pharmacology2023-1-16DOI: 10.3389/fphar.2023.1099927
1被引7阅读
引用收藏
分享

摘要

Background: Although the role of tumor microenvironment in lung adenocarcinoma (LUAD) has been explored in a number of studies, the value of TME-related signatures in immunotherapy has not been comprehensively characterized. Materials and Methods: Consensus clustering was conducted to characterize TME-based molecular subtypes using transcription data of LUAD samples. The biological pathways and immune microenvironment were assessed by CIBERSORT, ESTIMATE, and gene set enrichment analysis. A TME-related risk model was established through the algorithms of least absolute shrinkage and selection operator (Lasso) and stepwise Akaike information criterion (stepAIC). Results: Four TME-based molecular subtypes including C1, C2, C3, and C4 were identified, and they showed distinct overall survival, genomic characteristics, DNA methylation pattern, immune microenvironment, and biological pathways. C1 had the worst prognosis and high tumor proliferation rate. C3 and C4 had higher enrichment of anti-tumor signatures compared to C1 and C2. C4 had evidently low enrichment of epithelial-mesenchymal transition (EMT) signature and tumor proliferation rate. C3 was predicted to be more sensitive to immunotherapy compared with other subtypes. C1 is more sensitive to chemotherapy drugs, including Docetaxel, Vinorelbine and Cisplatin, while C3 is more sensitive to Paclitaxel. A five-gene risk model was constructed, which showed a favorable performance in three independent datasets. Low-risk group showed a longer overall survival, more infiltrated immune cells, and higher response to immunotherapy than high-risk group. Conclusion: This study comprehensively characterized the molecular features of LUAD patients based on TME-related signatures, demonstrating the potential of TME-based signatures in exploring the mechanisms of LUAD development. The TME-related risk model was of clinical value to predict LUAD prognosis and guide immunotherapy.

学科与关键词

关键词
lung adenocarcinomamolecular subtypesimmunotherapycisplatinpaclitaxelDNA methylation
相关
加载中…
  • Characterization of lung adenocarcinoma based on immunophenotyping and constructing an immune scoring model to predict prognosis
    Liu, Mengfeng; Xiao, Qifan; Yu, Xiran; Zhao, Yujie; Qu, Changfa*Frontiers in Pharmacology, 2022, 13: 1081244.
  • Characterization of the Immune Cell Infiltration Landscape Uncovers Prognostic and Immunogenic Characteristics in Lung Adenocarcinoma
    Wang, Xin; Xu, Zhenyi; Liu, Zhilin; Lin, Weihao; Cao, Zheng; Feng, Xiaoli; Gao, Yibo*; He, Jie*Frontiers in Genetics, 2022, 13: 902577.被引 2
  • LATPS, a novel prognostic signature based on tumor microenvironment of lung adenocarcinoma to better predict survival and immunotherapy response
    Huang, Jihong; Yuan, Lu; Huang, Wenqi; Liao, Liwei; Zhu, Xiaodi; Wang, Xiaoqing; Li, Jiaxin; Liang, Wenyu; Wu, Yuting; Liu, Xiaocheng; Yu, Dong; Zheng, Yunna; Guan, Jian*; Zhan, Yongzhong*; Liu, Laiyu*Frontiers in Immunology, 2022, 13: 1064874.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2023-01-16
卷期
第 14 卷
页码
1099927
DOI
10.3389/fphar.2023.1099927
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82072027]; Heilongjiang Postdoctoral Fund [LBH-Z18120]; Heilongjiang Applied Technology Research and Development Program Project [GA20C009]; Haiyan Medical Research Foundation [JJZD 2021-03]; Beijing Medical Award Foundation [YXT2-2021-0166-0183]

作者

  • J

    Jie, Yamin (第一作者)

    harbin med univ

  • W

    Wu, Jianing

    harbin med univ

查看全部 8 位作者收起作者
  • A

    An, Dongxue

    harbin med univ

  • L

    Li, Man

    harbin med univ

  • H

    He, Hongjiang

    harbin med univ

  • W

    Wang, Duo

    2 · harbin med univ

  • G

    Gu, Anxin (通讯)

    harbin med univ

  • M

    Mingyan, E. (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417